Watch live and recorded press conferences at https://www.acs.org/content/acs/en/pressroom/news-room/press-conferences.html. Press conferences will be held Monday, Aug. 17 through Thursday, Aug. 20, 2020
A new study upends the widely held belief that a medication used to treat lymphatic filariasis doesn’t directly target the parasites that cause the disease. The research shows the medication, diethylcarbamazine, temporarily paralyzes the parasites.
Scientists at La Jolla Institute for Immunology (LJI) have tracked down the rare stem cells that generate neutrophils in human bone marrow. This research, published August 18, 2020, in Immunity, gives researchers a potential path for intervening in diseases where neutrophil development goes awry.
In a new article published in Nature Communications, Moffitt Cancer Center researchers describe a novel acidic niche within lymph nodes that plays an integral role in regulating T cell activation.
Mild cases of coronavirus disease 2019 (COVID-19) can trigger robust memory T cell responses, even in the absence of detectable virus-specific antibody responses, researchers report August 14 in the journal Cell.
A Rutgers-led team may have found the key to treating inflammatory diseases like asthma, allergies, chronic fibrosis and chronic obstructive pulmonary disease (COPD).
A press conference on this topic will be held Tuesday, Aug. 17, at 10 a.m. Eastern time online at www.acs.org/fall2020pressconferences.
Today, scientists report a new immunotherapy that extends the survival of mice that have triple negative breast tumors, a difficult-to-treat form of cancer. The researchers will present their results at the American Chemical Society Fall 2020 Virtual Meeting & Expo.
Keck Medicine of USC launches phase 3 trial for COVID-19 vaccine. To ensure access for underrepresented and vulnerable populations, researchers are setting up a satellite location in the meat-packing community of Vernon, CA.
To protect humans against infection, a protein called MARCH8 tags the vesicular stomatitis virus (VSV) for destruction while it merely holds HIV hostage, a new study in eLife shows.
In a mouse study, researchers at Washington University School of Medicine in St. Louis have found that an antibody that targets the protein TREM2 empowers tumor-destroying immune cells and improves the effectiveness of cancer immunotherapy.
This research shows that both Pseudomonas and Burkholderia use toxic weaponry, called Type VI Secretion Systems (T6SS), to compete with and establish dominance over each other. It could be possible to target or mimic this weaponry to defeat the bacteria before they cause irreparable lung damage.
Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease
Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.
The Cancer Research Institute (CRI), a U.S. nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all cancers, awarded more than $30.2 million in research grants and fellowships in the 2020 fiscal year ending June 30, 2020.
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19.
Researchers at Yale University School of Medicine have developed a new mouse model to study SARS-CoV-2 infection and disease and to accelerate testing of novel treatments and vaccines against the novel coronavirus. The study, published today in the Journal of Experimental Medicine (JEM), also suggests that, rather than protecting the lungs, key antiviral signaling proteins may actually cause much of the tissue damage associated with COVID-19.
Novel Chromatinase™ platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19
A study led by Charité - Universitätsmedizin Berlin and the Max Planck Institute for Molecular Genetics (MPIMG) shows that some healthy individuals possess immune cells capable of recognizing the novel coronavirus, SARS-CoV-2.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right